Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | STK4 | Q13043 | 1/20 | 0.30 |
| ▸ | STK3 | Q13188 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669587 | 0.88 | CXCR3 (0.38) | COMTFTOMAPK1CXCR3NPC1 | |
| SCHEMBL32669636 | 0.82 | COMT (0.37) | COMTFTOMAPTKMT2A | |
| SCHEMBL32670093 | 0.82 | FTO (0.56) | COMTFTOMAPK1MAPTRAB9A | |
| SCHEMBL32669677 | 0.80 | COMT (0.32) | COMTFTO | |
| SCHEMBL32669807 | 0.79 | FTO (0.46) | COMTFTOMAPK1MAPTKMT2A | |
| SCHEMBL32669876 | 0.78 | ACHE (0.41) | COMTFTONPC1RAB9AKMT2A | |
| SCHEMBL32669976 | 0.78 | FTO (0.40) | COMTFTO | |
| SCHEMBL32669608 | 0.77 | FTO (0.37) | COMTFTO | |
| SCHEMBL32669684 | 0.77 | FTO (0.47) | COMTFTOMAPTKMT2A | |
| SCHEMBL32669799 | 0.74 | FTO (0.43) | COMTFTOMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | COMT 52/4885FTO 1/4885MAPK1 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.